THE NEW ERA OF
DRUG DIVERSION SURVEILLANCE

A 2026 MARKET ANALYSIS

Foreword – Beyond the Algorithm

The imperative for a robust drug diversion program within any healthcare setting remains as critical today as it has ever been. As established in previous analyses, drug diversion poses a tripartite threat: it compromises patient safety, endangers the well-being of the healthcare professionals (HCPs) ensnared by substance use disorder, and exposes the healthcare facility to severe financial, legal, and reputational damage.[1] A comprehensive monitoring program is not an administrative luxury but a fundamental pillar of any serious patient safety initiative, equivalent in importance to programs targeting falls or central line infections.[1]

However, since the last comprehensive review in late 2022, the landscape of drug diversion surveillance has undergone a tectonic shift. The market has been reshaped by a wave of strategic acquisitions, transforming a field of niche, specialized vendors into an ecosystem dominated by large, integrated health-tech corporations. This consolidation has fundamentally altered the products, service models, and strategic considerations that healthcare leaders must now navigate.

This report serves as an essential guide for this new and more complex era. Its purpose extends beyond a simple comparison of software features. It provides a deep analysis of the strategic implications of this market consolidation, evaluates the bifurcation of service models that has emerged as a result, and reinforces the immutable truth that technology is only a tool; its success is ultimately determined by the human factor—the expertise, resources, and processes that wield it.[1]

This analysis is designed to equip pharmacy directors, compliance officers, and diversion specialists with the nuanced understanding required to select not just a product, but a true strategic partner for their diversion prevention programs.

The Shifting Landscape: Consolidation, Suites, and Service Models

The drug diversion monitoring market of 2026 bears little resemblance to that of previous years. A series of strategic acquisitions has fundamentally altered the competitive landscape, giving rise to new service delivery paradigms and presenting healthcare organizations with a new set of strategic choices. Understanding these macro trends is essential context for evaluating individual vendors and their offerings.

The Great Consolidation: A Strategic Analysis

The most significant development in the drug diversion surveillance market has been its rapid consolidation, driven by larger healthcare technology firms acquiring specialized diversion analytics companies. This trend has effectively redrawn the industry map.

The key acquisitions that have defined this new era include:

- Wolters Kluwer acquired Invistics, rebranding its artificial intelligence (AI)-driven Flowlytics product as the Sentri7 Drug Diversion solution, incorporating it into a broader clinical surveillance platform.[2]
- Bluesight executed a multi-stage consolidation, acquiring Medacist (provider of RxAuditor Investigate) and, more recently, Protenus. These acquisitions have been integrated into Bluesight's Medication Intelligence™ platform, which is centered around its flagship ControlCheck product.[3]
- Quva Pharma, a prominent 503B sterile compounding company, acquired LogicStream Health. The software has since been rebranded as Quva BrightStream, creating a unique fusion of pharmaceutical services and data analytics.[5]
- Imprivata, a leader in digital identity and access management, acquired Fairwarning. The diversion monitoring solution is now fully integrated and offered as Imprivata Drug Diversion Intelligence.[8]
- Omnicell acquired Anigent, the creator of MAAP Analytics. This recent acquisition marks a significant pivot for Omnicell, moving it from a hardware-focused vendor relying on partners to one with its own premium, clinician-designed diversion analytics capabilities. This move integrates Anigent's unique waste assay and reconciliation features into Omnicell's broader medication management portfolio.

This wave of acquisitions is not coincidental but rather a calculated response to a powerful market driver: the concurrent consolidation within the healthcare provider industry itself.[10] Over the past decade, hospitals and health systems have been merging at an accelerated rate, creating large, multi-state enterprises.[11] The IT and compliance leadership within these newly formed mega-systems are under immense pressure to simplify their technology ecosystems, reduce the administrative burden of managing dozens of disparate vendors, and improve data interoperability across their organization.[12]

In response, larger technology vendors are pursuing a "suite" strategy. They are building comprehensive, integrated platforms that offer a single point of contact for a wide range of hospital pharmacy and compliance needs, including diversion monitoring, patient privacy auditing, inventory optimization, 340B compliance, and more.[8] By acquiring best-in-class diversion analytics tools, companies like Wolters Kluwer and Bluesight can offer a more complete and attractive package to large health systems that are looking to consolidate their own vendor relationships. This dynamic reveals that the transformation of the diversion software market is a direct, second-order effect of the broader consolidation trends within the American healthcare system.

The Service Model Bifurcation: SaaS vs. High-Touch Partnership

The consolidation of the market has led to a noticeable divergence in how vendors deliver their solutions and support their clients. This bifurcation can be broadly characterized as a standardized Software as a Service (SaaS) model, favored by the large consolidated players, and a more traditional, high-touch partnership model, often retained by the smaller, independent innovators.

The SaaS model, in which software is licensed on a subscription basis and centrally hosted, offers significant advantages that align with the goals of large vendors and their enterprise clients. It provides scalability, reduces the need for significant upfront capital investment in hardware, and lessens the implementation and maintenance burden on a hospital's internal IT department.[16] This model is ideal for delivering a standardized, efficient solution to a large and diverse customer base.

However, this standardization has potential trade-offs. A vendor serving a large suite of customers may adopt a more formalized and committee-based approach to product enhancements. Feature requests are no longer driven by the needs of a single, highly engaged client—a common dynamic when products were in earlier development stages—but are instead prioritized based on their benefit to the entire customer collective. This can result in a slower pace for bespoke customizations and a feeling of diminished individual influence for any single client.

In contrast, smaller, independent vendors that have not been acquired often continue to operate on a more agile, high-touch partnership model. These companies, by necessity, and by culture, may be more responsive to individual customer requests and more willing to engage in collaborative development, effectively treating clients as design partners. This can foster a strong sense of partnership and result in a solution that is highly tailored to a facility's unique workflows. The corresponding trade-off is that these smaller firms may have more limited resources for research, development, and large-scale support compared to their larger, well-capitalized competitors. This presents a clear choice for potential buyers: the scale, integration, and stability of a large SaaS provider versus the agility, customization, and personalized attention of a smaller, independent specialist.

The Human Element: In-House, Managed, or Outsourced Expertise

A third, and increasingly important, dimension of the service landscape is the formal recognition that software alone is insufficient for success. A recurring theme in both the 2019 and 2022 analyses was that the effectiveness of any diversion software is critically dependent on the facility having a designated, expert individual to oversee and interpret its output.[1] The market has matured to the point where this "expertise gap" is now being directly addressed and monetized through formal service offerings.

Three primary models have emerged:

Vendor-Provided Managed Services: his model is best exemplified by Imprivata, which offers a dedicated Drug Diversion Intelligence analyst as a component of its service package.[8] This is an attempt to bundle the solution to the expertise problem directly with the software. The vendor provides the human capital to perform the day-to-day monitoring, analyze alerts, and escalate potential cases to the facility's diversion team. The value of this model is highly variable and contingent upon the specific skill, experience, and diligence of the assigned analyst.

Third-Party Outsourcing (DMaaS): A distinct and growing alternative is Drug Diversion Monitoring as a Service (DMaaS), offered by specialized, vendor-agnostic consultancies such as Rxpert Solutions.[19] In this model, a healthcare facility procures its own surveillance software but contracts with an external firm of diversion experts to perform the monitoring, auditing, and analysis.[19] This approach unbundles the software from the human expertise, allowing a facility to choose the best technology for its needs while ensuring it is monitored by seasoned professionals. This model is particularly valuable for facilities that lack the resources or desire to hire, train, and retain a full-time, in-house diversion specialist.[19]

In-House Staffing: The Expertise Development Model: The traditional model involves hiring staff in-house to manage the diversion monitoring program. However, since not everyone is an expert, there are often significant gaps while staff is learning not only the software but also how to identify diversion and how to look for it within the data. Facilities often hire a pharmacy technician for this role. While they have the potential to become great diversion specialists depending on their traits and skill set, they are often starting from scratch with the concept of diversion as well as the software, and they have no clinical knowledge. Anyone placed in that role that does not have the needed traits or experience with diversion or the software will have a long period of learning, during which time the facility's monitoring program may be less effective.

The rise of these service-based models signifies a crucial evolution in the market's value proposition. The industry is moving beyond simply selling a technological tool and is now focused on delivering a complete solution to the complex operational challenge of diversion monitoring. This requires a sophisticated combination of advanced software and expert human analysis, whether provided in-house, by the software vendor, or through a dedicated third-party service.

Vendor Deep Dive Part I: The Consolidated Players

The recent wave of acquisitions has created a new class of vendors in the drug diversion monitoring space. These "consolidated players" are divisions within larger healthcare technology corporations, and their products are increasingly positioned as integral components of broader enterprise suites. Understanding their technology, strategy, and market approach is key to navigating the current landscape.

Omnicell: Integrating Anigent (MAAP Analytics)

Omnicell has recently announced the acquisition of Anigent, signaling a major strategic shift in its approach to drug diversion. Historically, Omnicell focused on inventory optimization software and partnered with third-party vendors for premium diversion analytics. With this acquisition, Omnicell now owns a best-in-class, clinician-designed analytics platform, moving Anigent from the "Independent Innovator" category to a "Consolidated Partner."

While the acquisition has been announced, Omnicell is currently in the process of operationalizing the merger. The full rollout to customers has not yet occurred, and the company is working through how Anigent's technology will be incorporated into its broader "Autonomous Pharmacy" suite. Details regarding future pricing, support models, and feature integration are expected to be released soon.

The core asset acquired is Anigent's MAAP (Medication Administration and Analytics Program) Analytics platform. Its most significant technical differentiator is the robust integration of waste analysis. MAAP is one of the few platforms to explicitly incorporate data from waste reconciliation and laboratory waste assays as a primary data source. This capability allows for the scientific verification of whether a returned substance is the correct drug at the expected concentration, providing a powerful tool against therapeutic substitution. By combining this specialized software with Omnicell's extensive hardware footprint, the company is positioning itself to offer a deeply integrated, end-to-end medication management solution.

Wolters Kluwer: Sentri7 Drug Diversion

Formerly known as Flowlytics by Invistics, a standalone vendor noted for its AI capabilities in the 2019 and 2022 reviews, the product is now fully integrated into the Wolters Kluwer ecosystem as the Sentri7 Drug Diversion solution.[2] This strategic move places the diversion tool within a comprehensive Clinical Surveillance Suite that operates on the unified SoleSource® platform. This suite also offers solutions for infection prevention, antimicrobial and opioid stewardship, and general pharmacy surveillance, allowing hospitals to standardize multiple clinical programs under a single vendor.[14]

The core technology of Sentri7 remains rooted in the AI and machine learning engine developed by Invistics. The system is designed to reconcile drug transactions from purchase to patient, rapidly identifying patterns of behavior consistent with diversion.[20] According to Wolters Kluwer, the platform assesses and weighs over 60 distinct determinants of risk by integrating data from sources including Automated Dispensing Cabinets (ADC), Electronic Health Records (EHR), wholesaler purchasing systems, time and attendance logs, and IV infusion data. This analysis culminates in a proprietary HEAT™ score, which highlights a staff member's cumulative risk compared to their peers, providing targeted insights for investigators.[21]

A foundational case study, conducted at Piedmont Athens Hospital when the product was still Flowlytics, provides strong evidence of the engine's efficacy. The research, which was supported by a grant from the National Institutes of Health, found that the machine learning algorithms successfully detected all nine pre-identified, known cases of diversion at the facility. Crucially, the system flagged these cases as suspicious well before traditional investigative timelines would have caught them.[22]

Wolters Kluwer is positioning Sentri7 not just as a diversion tool, but as a critical component of an enterprise-wide strategy for improving patient safety, ensuring regulatory compliance, and driving operational efficiency. Their value proposition is enhanced by the resources of the parent company, which include dedicated customer success managers and implementation teams, aiming to provide a consistent and well-supported experience for large health systems.[14]

Bluesight: ControlCheck and the Medication Intelligence™ Platform

Bluesight has pursued the most aggressive consolidation strategy in the market, transforming itself into a dominant force in medication intelligence. Through the acquisitions of Medacist (provider of the legacy RxAuditor software) and, more recently, Protenus, Bluesight has brought three historically distinct and competitive product lines under a single corporate umbrella.[4] This is particularly notable given that Protenus was the winner of the 2024 Best in KLAS award for Drug Diversion Monitoring, a significant achievement.[23]

The company's flagship offering is ControlCheck, itself a four-time Best-in-KLAS winner that is trusted by many of the nation's top health systems.[3] The platform is marketed as a comprehensive, end-to-end solution that provides surveillance across the full spectrum of care settings, including nursing units, the operating room (OR), and both inpatient and retail pharmacy operations.[3] Bluesight claims that ControlCheck detects drug diversion 6.6 times more effectively than competing next-generation solutions and achieves an impressive 95% automatic reconciliation rate for medication transaction audits.[3]

Technologically, ControlCheck synthesizes data from ADCs, EHRs, wholesaler purchasing logs, and time and attendance systems to perform closed-loop dose reconciliation.[3] A key proprietary feature is the Individual Risk Identification Score (IRIS), a worklist that uses behavioral analytics to prioritize reviews, allowing diversion teams to focus their efforts where risk is most likely.[3] The platform's design philosophy emphasizes interdisciplinary collaboration, offering unlimited user seats and promoting itself as "nurse-friendly" to encourage engagement beyond the pharmacy department.[3]

Bluesight's overarching market strategy is to offer a bundled suite of essential health system solutions—including diversion surveillance, RFID medication management, and purchasing optimization—under a single vendor contract, promising simplified processes and bundled savings.[15] Customer feedback collected by KLAS is largely positive, with users frequently citing the platform's ease of use, tangible time savings, and the vendor's proactive engagement and responsiveness to suggestions.[25] However, some customer comments indicate mixed results, with at least one user reporting that they left the platform because it had failed to identify any diversion events during their years of use.[25]

Quva Pharma: Quva BrightStream

The acquisition of LogicStream Health by Quva Pharma represents one of the most unique consolidation strategies in the market. Quva Pharma, primarily known as a large-scale 503B sterile compounding and outsourcing facility, has vertically integrated by acquiring a SaaS-based clinical analytics company.[5] This move creates a novel pharma-tech entity that combines the physical production and distribution of medications with the data intelligence required to monitor their use.

The resulting software solution, Quva BrightStream, is an AI-powered, cloud-based platform that performs active surveillance of controlled substance activity across a health system.[27] The system monitors every clinician and every transaction, analyzing more than 20 distinct behavioral signals to detect patterns indicative of diversion. It assigns clinicians a "Relative Risk Score" to streamline and prioritize investigations.[27] A key feature is its built-in workflow management system, which allows teams to document audits, assign tasks, and track observed behaviors entirely within the platform, aiming to replace inefficient and insecure spreadsheet-based investigation processes.[27]

The BrightStream platform reports impressive performance metrics, including a 95% auto-reconciliation rate for controlled substance dispenses and a 99.5% accuracy rate. It also claims that 34% of investigations launched through the platform have led to tangible clinical process improvements.[27] The system emphasizes peer-to-peer comparisons to provide context and reduce bias in its analysis, rolling up each clinician's activity into a unified profile that tracks their actions across all departments and sites of care.[27]

Quva's market position is that of an end-to-end partner for health-system pharmacies. The strategy is to create a symbiotic ecosystem where the data and insights from the BrightStream platform inform and enhance the pharmaceutical services offered by Quva Pharma, and vice versa.[5] This approach is supported by positive historical customer feedback. The 2022 white paper noted that a LogicStream client was "extremely satisfied" with the product and its performance.[1] Similarly, a 2021 KLAS report highlighted that customers who selected LogicStream praised the company for its "excellent relationships and good technology".[28]

imprivata®

Imprivata: Drug Diversion Intelligence (DDI)

Imprivata, a major player in the digital identity and secure access market for healthcare, entered the diversion space through its acquisition of Fairwarning. Fairwarning was a well-regarded leader in patient privacy monitoring, and its diversion solution has now been fully integrated into the Imprivata portfolio as Drug Diversion Intelligence (DDI).[8] The solution is part of the broader Imprivata Access Intelligence Platform, which also includes Patient Privacy Intelligence (PPI), allowing for unified monitoring of both privacy and diversion risks.[8]

The most significant differentiator for Imprivata's DDI is its optional managed services offering. Recognizing that many facilities lack the internal resources for constant monitoring, Imprivata provides a dedicated, vendor-employed DDI analyst who actively monitors the software, identifies risks, and collaborates with the client's diversion team.[8] This service model has proven to be a powerful selling point. Customer testimonials featured by Imprivata are compelling, with one Chief Pharmacy Officer from a multistate health system stating, "Our DDI analyst saves us at least 10 hours a day, which is easily the equivalent of a full-time hire".[8]

The DDI technology itself leverages AI and behavioral analytics to provide continuous monitoring of the entire controlled substance lifecycle, from dispensing and administration to waste.[8] The platform features user-based analytics, real-time alerts, intuitive dashboards, and guided workflows within its investigation module to promote efficiency and thoroughness.[8] The system is built on a secure and certified platform, holding SOC 2 Type 2, ISO 27001, and ISO 27701 certifications.[8] Recent product release notes indicate an ongoing focus on improving application performance, with screen load times decreased by as much as 60%, alongside a rebranding effort to fully integrate the Fairwarning acquisition into the Imprivata Digital Identity Intelligence suite.[30]

Imprivata is positioned as a comprehensive security and compliance partner for healthcare. The 2021 KLAS report confirmed that the availability of a dedicated managed service analyst was a primary reason why new customers selected the platform.[28] However, the value of this model is highly variable. Client satisfaction with the software seems to be largely driven by the analyst providing the managed service. Not all analysts are created equal, and some clients have reported that a change to a different analyst made a significant positive difference in their experience. This variability makes the skill and expertise of the assigned analyst a crucial factor for prospective clients to vet during the procurement process.

iatricSystems

iatricSystems: DetectRx

iatricSystems represents a different type of consolidated player. Rather than entering the market by acquiring a diversion analytics company, iatricSystems is a long-standing healthcare IT veteran that developed its DetectRx solution in-house, building out its existing portfolio.[31] With over 35 years of experience and a client base of more than 1,300 hospitals, the company brings a high degree of corporate stability, operating as an independent business unit of Harris Healthcare.[31]

The company's market position is built on its core strength in interoperability and its "suite" strategy. Its broader portfolio includes solutions for patient privacy (Haystack iS), clinical workflow (MobiLab), and extensive integration services, positioning DetectRx as one component of a comprehensive healthcare IT partnership.[31]

The DetectRx software ingests data from EMRs, ADCs, and timekeeping systems to create a complete view of medication-related activities.[33] Its analytical engine uses a hybrid of machine learning and expert-written rules to identify anomalies while reducing false positives, and it incorporates contextual data like pain scores to build a more nuanced risk profile.[33] A key potential differentiator is an AI-powered assistant named AVA, which is designed to automate the initial steps of an investigation by sending automated queries to managers about questionable transactions.[34] However, as public materials primarily associate AVA with the Haystack iS patient privacy product, prospective clients should seek direct confirmation of its functionality within the DetectRx workflow.[35] Client testimonials confirm the platform's value in identifying systemic practice gaps, positioning it as a quality improvement tool in addition to a diversion monitor.[33]

Vendor Deep Dive Part II:
The Independent Innovators & Ecosystem Players

While consolidation has reshaped the market, several key vendors remain independent or operate within a different type of ecosystem, such as one centered on medication dispensing hardware. These companies often compete by offering highly specialized functionalities, deep customization capabilities, or the advantages of a tightly integrated hardware-software environment.

HelioMetrics: The Customization & Data Validation Specialist

HelioMetrics has carved out a distinct niche in the market by focusing on deep customization. Their platform is marketed as a highly customizable solution designed to empower healthcare systems to build a monitoring program that precisely matches their internal policies and procedures.[41] While all modern diversion software vendors can integrate with various EHR and ADC systems, HelioMetrics emphasizes this flexibility as a core competitive advantage, allowing them to integrate data from multiple, disparate systems into a single, unified interface—a crucial capability for large health systems that have grown through mergers and acquisitions and now operate a patchwork of legacy technologies.[42]

A second cornerstone of the HelioMetrics approach is a rigorous focus on data integrity. The company emphasizes its extensive and robust data validation process as a key part of its service, working closely with clients to ensure that only clean, reliable data is ingested into the analytics platform.[41] This directly addresses one of the most common and time-consuming challenges of any diversion software implementation, as noted in the 2022 review, and is designed to significantly reduce the rate of false-positive alerts.[1]

The platform's technology is built on a proprietary "Diversion Triangulation™" methodology, which correlates data from EHR, ADC, timekeeping, and HR systems to build comprehensive user profiles and behavioral baselines.[42] Notably, HelioMetrics is the only vendor that claims to fully integrate and link pain score data into its analytics, allowing investigators to correlate medication administration with documented patient outcomes.[41] The company offers distinct modules for general healthcare (nursing and anesthesia), pharmacy supply chain, and physician prescribing practices (opioid stewardship).[42] While customer testimonials praise the platform for dramatically reducing investigation time [44], a 2021 KLAS report indicated that some prospective customers had concerns about the technology being weaker than competitors' and more focused on retrospective, rather than proactive, analysis.[28]

BD: HealthSight Diversion Management

BD (Becton, Dickinson and Company) leverages its dominant position in the medication management hardware market to offer a powerful and deeply integrated diversion monitoring solution. The BD HealthSight Diversion Management application is designed to work seamlessly within the broader BD ecosystem, particularly

with its market-leading Pyxis™ Automated Dispensing Cabinets.[45] This tight integration between hardware and software creates a compelling value proposition for the thousands of hospitals that already rely on BD for their medication distribution infrastructure.

The HealthSight platform utilizes advanced analytics powered by machine learning to identify anomalous behavior. Rather than relying on simple statistical outliers, the system compares an individual clinician's behavior against a dynamically selected and contextually relevant peer group.[47] It analyzes a variety of signals beyond mere dispense counts, including patterns of overrides, cancelled transactions, and unusual delays between dispensing, administration, and wasting—behaviors that are often more indicative of diversion.[45]

The solution is a hosted, cloud-based application that automates the time-consuming process of reconciling ADC transaction logs with administration data from the EMR, automatically flagging discrepancies that may require investigation.[47] The effectiveness of this approach was demonstrated in a recent research study conducted at Ochsner Health. The study, published in the American Journal of Health-System Pharmacy, found that implementing BD HealthSight led to a 55% increase in the number of charting discrepancies identified, due to the software's ability to track a broader range of high-risk behaviors. More importantly, it dramatically improved efficiency, reducing the time required for a full audit of a referred case from an average of three business days down to just 50 minutes.[48] BD's market strategy is to provide a holistic, enterprise-wide medication management platform, with diversion management as a critical software layer on top of its robust hardware foundation.

2026 Drug Diversion Software Master Comparison

The following table provides a consolidated, at-a-glance comparison of the leading drug diversion surveillance solutions on the market as of early 2026. It is designed to synthesize the detailed vendor analysis and highlight the key strategic and technical differentiators that healthcare leaders should consider during the procurement process. The columns have been updated to reflect the new market realities of consolidation, integrated technology suites, and diverse service models.

Vendor/Product Name	Sentri7 Drug Diversion	ControlCheck	Quva BrightStream
Parent Company / Suite Integration	Wolters Kluwer / SoleSource Clinical Surveillance Suite	Bluesight / Medication Intelligence Platform	Quva Pharma / Pharmacy Ecosystem
Primary Service Model	SaaS	SaaS	SaaS
Core Analytical Engine	AI/Machine Learning	AI/Machine Learning, Behavioral Analytics	AI/Machine Learning, Clinical Rules Processing
Key Differentiator (Vendor-Stated)	Integration into a broad clinical surveillance suite; HEATα risk score	4x Best-in-KLAS winner; 95% auto-reconciliation; IRIS worklist	Integration of pharma services with data analytics; Relative Risk Score
Data Sources Integrated	ADC, EHR, Purchasing, Inventory, Time/Attendance	ADC, EHR, Purchasing, Vault, Time/Attendance	ADC, EHR, Prescribing Data
Monitors Full Medication Lifecycle	Yes (Purchase to Patient)	Yes (Wholesaler to Reverse Distributor)	Yes (Tracks prescribing, dispensing, administration)
KLAS Recognition (2024/2025)	#1 for Infection Control & Monitoring (Sentri7 Suite)	High KLAS ratings; "Best in KLAS" in prior years	Not ranked in 2024
Target Market	Large Health Systems seeking vendor consolidation	All Facilities, especially those seeking a proven, collaborative platform	Health Systems seeking an integrated pharma-tech partner
Notes/Strategic Considerations	Leverages strong AI engine from Flowlytics. Value proposition is tied to adopting the broader WK clinical platform.	Market leader with strong customer satisfaction. Recent acquisitions of Protenus and Medacist expand its capabilities and customer base.	Unique market position combining 503B compounding with analytics. Positive historical feedback on technology and relationships.

Vendor/Product Name	HelioMetrics	HealthSight Diversion Management	MAAP Analytics
Parent Company / Suite Integration	HelioMetrics (Independent)	BD / Medication Management Ecosystem	Omnicell (Formerly Anigent)
Primary Service Model	High-Touch/Custom	SaaS	SaaS / Integrated Ecosystem
Core Analytical Engine	Statistical Analysis, Behavioral Patterns	Machine Learning	Applied Intelligence, Machine Learning
Key Differentiator (Vendor-Stated)	Fully customizable platform; pain score integration	Deep integration with Pyxis hardware ecosystem	The only platform to integrate waste reconciliation and lab essays
Data Sources Integrated	ADC, EHR, Timekeeping, HR, Pain Scores	ADC (Pyxis), EHR	ADC, EHR, Inventory, Waste Retrieval, Waste Assay
Monitors Full Medication Lifecycle	Yes (Wholesaler to Reverse Distributor)	Yes (Automates reconciliation)	Yes (Monitors all users. meds, locations)
KLAS Recognition (2024/2025)	Not ranked in 2024	Not ranked in 2024	Not ranked in 2024
Target Market	Health systems with multiple, disparate IT systems needing a unified view	Hospitals heavily invested in the BD/Pyxis hardware ecosystem	Omnicell hardware users; facilities seeking deep waste verification.
Notes/Strategic Considerations	Competes on flexibility and data integrity. Strong choice for complex environments, but some perceive technology as less advanced.	Powerful ecosystem play. Ochsner case study demonstrates significant efficiency gains. Vendor has historically declined to participate in reviews	Now part of Omnicell's portfolio. Combines Anigent's unique waste features with Omnicell's hardware ecosystem. Currently in initial "soft launch" phase post-acquisition.

Vendor/Product Name	Imprivata	DetectRx
Parent Company / Suite Integration	Imprivata / Digital Identity Intelligence Suite	iatricSystems (Harris Healthcare) / Clinical & Compliance Suites
Primary Service Model	SaaS with Managed Service Option	SaaS
Core Analytical Engine	AI/Behavioral Analytics	AI/Machine Learning + Expert Rules
Key Differentiator (Vendor-Stated)	Optional dedicated analyst to monitor software for the client	AI Assistant (AVA) for automated investigation follow-up; deep integration expertise. [33]
Data Sources Integrated	ADC, EHR, Pharmacy, HR Systems	ADC, EHR, Timekeeping
Monitors Full Medication Lifecycle	Yes (Prescription to Administration)	Yes (ADC to Administration/Waste)
KLAS Recognition (2024/2025)	Not ranked in 2024	Not ranked in 2024
Target Market	Facilities lacking in-house expertise or resources for monitoring	Health systems needing strong integration capabilities
Notes/Strategic Considerations	The managed service is a key differentiator, but its value is highly dependent on the skill of the assigned analyst	Long-standing IT parent company provides stability. The AVA feature is a potential game-changer, but its functionality for diversion must be verified.

A Modern Framework for Selecting a Diversion Partner

The consolidation of the market and the evolution of service models demand a more sophisticated framework for selecting a drug diversion monitoring solution. The decision is no longer a simple comparison of software features; it is a strategic choice about technology, service, and the allocation of a facility's own precious human resources. The key takeaways from the 2022 review remain valid, but they must be applied through the lens of this new market reality.[1]

It's Not Just Software, It's a Strategy: Aligning Models with Resources

The most critical first step in the selection process is a rigorous and honest internal assessment. Before engaging with any vendors, a facility's leadership team must answer several foundational questions: Do we have a dedicated, trained, and certified drug diversion specialist on staff? If not, do we have the budget and ability to hire one? How many full-time equivalent (FTE) hours can our existing pharmacy, nursing, and compliance staff realistically dedicate to monitoring software output and conducting investigations?.[19] The answers to these questions will determine which service and technology model is the best strategic fit.

A potential decision-making framework could be structured as follows:

For facilities with high in-house expertise and dedicated resources: A powerful, feature-rich SaaS platform from a vendor like Wolters Kluwer's Sentri7, Bluesight, Quva, or Omnicell (MAAP Analytics) may be the ideal choice. These tools provide a capable internal team with the advanced analytics needed to conduct sophisticated surveillance efficiently.

For facilities with moderate expertise but limited FTEs: A managed service model, such as that offered by Imprivata, presents a compelling option. This approach supplements the internal team by outsourcing the time-consuming task of daily monitoring to a vendor-provided analyst, freeing the in-house specialist to focus on investigations and program management.

For facilities with limited in-house expertise and resources: A fully outsourced DMaaS model from a specialized firm like Rxpert Solutions could provide the highest return on investment. This strategy allows the facility to leverage its software investment while ensuring that the data is being interpreted by dedicated experts, without the significant overhead of hiring and training a new internal team.[19]

For facilities with unique workflows or complex, multi-vendor IT environments: An independent innovator like HelioMetrics or Anigent, or a consolidated player with deep integration expertise like iatricSystems, might be the most suitable partner. Their emphasis on customization and ability to integrate disparate data sources can provide a tailored solution that may not be possible with a more standardized SaaS platform.[39]

The Non-Negotiable Human Factors

Regardless of the chosen technology or service model, several human-centric factors remain non-negotiable for the success of any diversion monitoring program.

First, if a facility opts for a managed service, the **analyst variable is paramount.** The value of the service is not determined by the software, but by the skill of the human being interpreting it. During the procurement process, facilities must press vendors for details on the qualifications of their analysts. Inquiries should be made about their clinical background, their specific training in diversion detection, and their years of experience.

Second, **data validation is still mandatory.** No software or service can function effectively with inaccurate or poorly mapped data. The principle of "garbage in, garbage out" is an absolute.[1] The facility's team must be prepared to invest significant time during implementation to validate that data feeds from the EHR, ADCs, and other sources are transferring correctly and that the software's logic is being applied appropriately to the facility's specific workflows. The fact that a vendor like HelioMetrics has built a core part of its service offering around assisting with this painful process highlights its critical importance.[41]

Finally, it must be understood that **client expertise ultimately determines outcomes.** Diversion surveillance software is an investigative tool, not an automated enforcement system. It guides a skilled investigator toward anomalies and patterns that warrant a deeper look; it does not, on its own, "find diversion".[1] The ability of the facility's diversion officer or committee to take the software's output, apply clinical context, conduct a thorough investigation, and perform effective interviews is what transforms a high-risk score into a confirmed case and a successful intervention. As one study noted, a seasoned diversion coordinator is essential to evaluate if a software's intelligence translates into the "real world" of diversion.[51]

Future-Proofing Your Diversion Program

Selecting a diversion partner is a long-term commitment. Therefore, it is crucial to look beyond a vendor's current capabilities and evaluate its strategy for future innovation.

The entire market is moving decisively toward more sophisticated uses of AI and predictive analytics.[52] A 2025 report from Wolters Kluwer reveals a significant gap between desire and adoption: while 76% of survey respondents express a desire for increased use of AI technologies in diversion detection, only 37.5% currently report using them.[53] This indicates a market on the cusp of a technological leap. Facilities should closely scrutinize a vendor's technology roadmap. Key questions to ask include: What are your R&D investment priorities? How does your algorithm "learn" from client feedback and confirmed cases to become more accurate over time? What are your plans for integrating new and challenging data sources, such as infusion pump logs, which were noted as a pain point in previous reviews?.[18]

Furthermore, as facilities consider partnering with one of the large, consolidated vendors, they must strategically evaluate the risk of "suite" lock-in. While the convenience of an integrated platform is appealing, it can create significant dependency on a single vendor. Before signing a long-term agreement for a multi-product suite, healthcare leaders should ensure the contract includes clear service-level agreements (SLAs) for each module, guarantees of data ownership, and well-defined processes for data portability should the facility choose to switch vendors in the future. A thorough analysis of the total cost of ownership for an entire suite versus a collection of individual best-of-breed solutions is an essential exercise in due diligence.

Conclusion:
Navigating the New Normal in Diversion Monitoring

The landscape of drug diversion surveillance has been irrevocably altered. The market is now defined by a new paradigm of consolidation, where major healthcare technology corporations offer diversion monitoring as a key component of broad, integrated enterprise suites. This shift has driven the evolution of service models, creating a spectrum of options ranging from highly standardized SaaS platforms to bespoke, high-touch partnerships and fully outsourced expert monitoring services. The role of artificial intelligence is no longer a future concept but a present-day reality, serving as the core engine for nearly every leading solution.

In this new normal, the process of selecting a partner requires a more strategic and introspective approach than ever before. Healthcare leaders must begin by looking inward, performing a candid assessment of their own organization's resources, expertise, and operational realities. This self-assessment is the essential first step to determining which technology and service model represents the best strategic fit.

Ultimately, however, the foundational principles of a successful diversion prevention program remain unchanged. Technology, no matter how sophisticated, is a powerful enabler, not a panacea. It will never replace the need for a strong organizational culture of safety and accountability, where staff feel empowered to report concerns without fear of retribution.[1] It cannot substitute for clear, well-designed policies and procedures that govern every step of the medication-use process. A critical component of this is a well-defined Standard Operating Procedure (SOP) for responding to a suspected diversion. This SOP must clearly delineate who is notified and involved, how an intervention is conducted, and who makes the final decisions on next steps and outcomes. Most importantly, technology cannot replicate the nuanced judgment and clinical expertise of a dedicated, knowledgeable human being at the helm of the program.

The goal for any healthcare facility should be to select a long-term partner whose technology and service model will augment and empower its people, streamline its processes, and fortify its culture. By using this analysis to ask more incisive questions and to think more strategically about the interplay between technology and human capital, healthcare organizations can confidently navigate this new landscape and build a diversion monitoring program that is both effective and sustainable.

RXPERT
SOLUTIONS

About Rxpert Solutions

Rxpert Solutions is a leading provider of drug diversion mitigation and monitoring services, helping clients achieve their compliance and safety goals by mitigating the risks inherent with diversion of controlled substances. Allow us to partner with you in performing a risk assessment to find your vulnerabilities in controlled substance security, policies and procedures, workflows and education. If your facility has a third-party surveillance software solution, Rxpert Solutions can help you maximize your investment. We provide expert Drug Diversion Monitoring as a Service (DMaaS) through a comprehensive and consultative partnership specifically designed to assist healthcare

facilities. To learn more about Rxpert Solutions and how we can help your facility, visit rxpert.solutions

Terri Vidals
Medication safety and drug diversion consulting services

Email: tvidals@rxpert.solutions

Works cited Whitepaper on the product review 2026

1. Whitepaper on the product review 2022
2. Diversion Software - New & Noteworthy - Pharmacy Purchasing & Products Magazine, accessed September 23, 2025, https://www.pppmag.com/new_noteworthy/?noteid=2334
3. Drug Diversion Monitoring & Detection Software: ControlCheck - Bluesight, accessed September 23, 2025, https://bluesight.com/drug-diversion-monitoring/
4. Bluesight Expands Compliance Capabilities and Strengthens ..., accessed September 23, 2025, https://bluesight.com/news/bluesight-expands-compliance-capabilities-and-strengthens-platform-through-acquisition-of-protenus/
5. Quva Pharma, accessed September 23, 2025, https://onequva.com/
6. LogicStream Health - Noro-Moseley Partners, accessed September 23, 2025, https://noromoseley.com/company/logicstream/
7. Quva Pharma Completes Acquisition of BrightStream Health, accessed September 23, 2025, https://onequva.com/news-and-events/press/quva-pharma-completes-acquisition-of-logicstream-health
8. Drug Diversion Monitoring Tools & Products | Imprivata, accessed September 23, 2025, https://www.imprivata.com/products/access-management/access-compliance/drug-diversion-intelligence
9. FairWarning Cloud Service Appendix - Imprivata, accessed September 23, 2025, https://www.imprivata.com/imprivata-master-cloud-services-agreement/fairwarning
10. The Impact of Healthcare Consolidation - Alliance for Physician ..., accessed September 23, 2025, https://apl.utdallas.edu/2019/01/03/346/
11. Health System Consolidation, accessed September 23, 2025, https://www.ncsl.org/health/health-system-consolidation
12. Why healthcare IT leaders care about vendor consolidation - Notable Health, accessed September 23, 2025, https://www.notablehealth.com/blog/why-healthcare-it-leaders-care-about-vendor-consolidation
13. How technology vendor consolidation impacts hospital cost savings and efficiency, accessed September 23, 2025, https://clarifyhealth.com/insights/blog/the-impact-of-technology-vendor-consolidation-on-hospital-cost-savings-and-efficiency/
14. Sentri7 - Clinical Surveillance Software - Wolters Kluwer, accessed September 23, 2025, https://www.wolterskluwer.com/en/solutions/sentri7-clinical-surveillance
15. Bluesight: Powering Your Hospital and Pharmacy Operations, accessed September 23, 2025, https://bluesight.com/
16. Saas for Healthcare Services - Healthie, accessed September 23, 2025, https://www.gethealthie.com/glossary/software-as-a-service-saas
17. SaaS Compliance Software for GDPR, HIPAA & PCI - Metomic, accessed September 23, 2025, https://www.metomic.io/solution/compliance
18. 2019 Drug Diversion Software Comparison Article
19. Drug Diversion Monitoring Service | DMaaS Solutions by Rxpert, accessed September 23, 2025, https://www.rxpert.solutions/solutions/drug-diversion-monitoring-as-a-service/
20. Three best practices for successful drug diversion prevention - Wolters Kluwer, accessed September 23, 2025, https://www.wolterskluwer.com/en/expert-insights/3-best-practices-for-successful-drug-diversion-prevention
21. Sentri7 Drug Diversion: Protect Patients, Ensure Compliance - Wolters Kluwer, accessed September 23, 2025, https://www.wolterskluwer.com/en/solutions/sentri7-clinical-surveillance/drug-diversion
22. Utilizing advanced technology to detect drug diversion: A Piedmont Athens case study, accessed September 23, 2025, https://www.wolterskluwer.com/en/expert-insights/utilizing-advanced-technology-detect-drug-diversion-healthcare-piedmont-athens-case-study
23. 2024 Best in KLAS Awards - Software and Services | KLAS Report, accessed September 23, 2025, https://klasresearch.com/report/2024-best-in-klas-awards-software-and-services/3413
24. ControlCheck™ Demo - Bluesight, accessed September 23, 2025, https://bluesight.com/resource/control-check-demo/
25. Bluesight ControlCheck - User Comments - KLAS Research, accessed September 23, 2025, https://klasresearch.com/comments/bluesight-controlcheck/197893
26. Bluesight Customers Report The Most Success In Seeing Tangible Outcomes, accessed September 23, 2025, https://bluesight.com/news/kit-check-customers-report-the-most-success-in-seeing-tangible-outcomes/
27. Drug Diversion Surveillance - Quva Pharma, accessed September 23, 2025, https://onequva.com/brightstream/drug-diversion-surveillance
28. Drug Diversion Monitoring January 2021 | KLAS Report, accessed September 23, 2025, https://klasresearch.com/report/drug-diversion-monitoring-2021-energy-high-for-next-generation-solutions-a-decision-insights-report/2020
29. Drug diversion and monitoring solutions | Imprivata, accessed September 23, 2025, https://www.imprivata.com/blog/drug-diversion-and-monitoring-solutions
30. What's New in Imprivata Access Intelligence 25.9, accessed September 23, 2025, https://imprivatadocs.com/aip/content/release%20notes/24.1/fw_release_notes_ext_24.1.html
31. Company - Healthcare IT Services & Solutions - Iatric Systems, accessed October 2, 2025, https://iatric.com/company/
32. Becoming part of the Harris family | Iatric Systems, accessed October 2, 2025, https://www.harriscomputer.com/news/en/ma-resourcesdate1615438800articlereal-experiences-becoming-part-of-the-harris-family-iatric-systems

33. Drug Diversion Software | DetectRx | Iatric Systems, accessed October 2, 2025, https://iatric.com/detectrx/
34. Drug Diversion Certificate - ASHP Learning Center, accessed September 23, 2025, https://elearning.ashp.org/products/12153/drug-diversion-certificate
35. AVA Video - Iatric Systems, accessed October 2, 2025, https://iatric.com/videos/advanced-virtual-assistant-ava-video/
36. iatricSystems | Healthcare IT Services & Solutions, accessed October 2, 2025, https://iatric.com/
37. From Data to Action: ANiGENT's MAAP Analytics® Integrated Drug Diversion Surveillance for Health Systems - RXinsider, accessed September 23, 2025, https://rxinsider.com/market-buzz/20868-from-data-to-action-anigent-rsquo-s-maap-analytics-reg-integrated-drug-diversion-surveillance-for-health-systems/
38. Interview with Anigent Chief Product Officer & Managing Partner Charles D'Amato., accessed September 23, 2025, https://www.youtube.com/watch?v=Bcv_CMTbgAA
39. maap analytics - ANiGENT, accessed September 23, 2025, https://anigent.com/maap-analytics/
40. Diversion Analytics in Minutes - RXinsider, accessed September 23, 2025, https://rxinsider.com/market-buzz/10104-diversion-analytics-in-minutes/
41. HelioMetrics | The Most Comprehensive Diversion Analytics Software - RXinsider, accessed September 23, 2025, https://rxinsider.com/market-buzz/20812-heliometrics-andnbsp-the-most-comprehensive-diversion-analytics-software/
42. HelioMetrics Healthcare Rx Drug Diversion Solutions, accessed September 23, 2025, https://heliometrics.net/wp-content/uploads/HelioMetrics-Drug-Diversion-Solutions-2022.12.02.pdf
43. HelioMetrics: Turning Rx Drug Diversion Data Into Actionable Intelligence - RXinsider, accessed September 23, 2025, https://rxinsider.com/market-buzz/heliometrics-turning-rx-drug-diversion-data-into-actionable-intelligence/
44. HelioMetrics – Healthcare Rx Drug and Pharmacy Diversion – Healthcare Rx Drug Diversion and Pharmacy Diversion Monitoring, accessed September 23, 2025, https://heliometrics.net/
45. BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion, accessed September 23, 2025, https://news.bd.com/2018-11-29-BD-Expands-Integrated-Medication-Management-to-Help-Tackle-Hospital-Drug-Diversion-1
46. BD HealthSight Diversion Management, accessed September 23, 2025, https://www.bd.com/en-us/videos/bd-healthsight-diversion-management
47. BD HealthSight™ Diversion Management - 1112-00 | BD, accessed September 23, 2025, https://www.bd.com/en-us/products-and-solutions/products/product-page.1112-00
48. New Data Reveals BD's Artificial Intelligence Software Highly ..., accessed September 23, 2025, https://investors.bd.com/news-events/press-releases/detail/851/new-data-reveals-bds-artificial-intelligence-software-highly-effective-in-detecting-indicators-of-controlled-substance-diversion
49. Inventory Optimization Service | Omnicell, accessed September 23, 2025, https://www.omnicell.com/central-pharmacy/inventory-optimization-service/
50. Points of Care - Omnicell, accessed September 23, 2025, https://www.omnicell.com/points-of-care/
51. Preparing for drug diversion software: Enhancing technologies and diversion prevention program growth | American Journal of Health-System Pharmacy | Oxford Academic, accessed September 23, 2025, https://academic.oup.com/ajhp/article/81/23/e788/7723742
52. How AI software enhances 8 critical monitoring practices for drug diversion - Wolters Kluwer, accessed September 23, 2025, https://www.wolterskluwer.com/en/expert-insights/the-impact-of-ai-surveillance-on-8-critical-monitoring-practices-for-drug-diversion-detection
53. The State of Drug Diversion Report | Wolters Kluwer, accessed September 23, 2025, https://www.wolterskluwer.com/en/expert-insights/the-state-of-drug-diversion-report